XML 49 R37.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Business Segments (Tables) | 9 Months Ended
--- | ---
Dec. 31, 2017
Segment Reporting [Abstract] |
Information about our Operating and Reportable Segments | The tables below summarize information about our reportable segments.
| Three Months Ended December 31, 2017
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  | Household Cleaning |  | Consolidated
Total segment revenues* | $ | 225,695 |  |  | $ | 25,717 |  |  | $ | 19,203 |  |  | $ | 270,615 |
Cost of sales | 95,164 |  |  | 10,511 |  |  | 17,266 |  |  | 122,941 |
Gross profit | 130,531 |  |  | 15,206 |  |  | 1,937 |  |  | 147,674 |
Advertising and promotion | 30,794 |  |  | 4,544 |  |  | 497 |  |  | 35,835 |
Contribution margin | $ | 99,737 |  |  | $ | 10,662 |  |  | $ | 1,440 |  |  | 111,839 |
Other operating expenses |  |  |  |  |  |  |  |  | 28,336 |
Operating income |  |  |  |  |  |  |  |  | 83,503 |
Other expense |  |  |  |  |  |  |  |  | 25,864 |
Income before income taxes |  |  |  |  |  |  |  |  | 57,639 |
Benefit for income taxes |  |  |  |  |  |  |  |  | (257,154 | )
Net income |  |  |  |  |  |  |  |  | $ | 314,793 |
* Intersegment revenues of $1.9 million were eliminated from the North America OTC Healthcare segment.
| Nine Months Ended December 31, 2017
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  | Household Cleaning |  | Consolidated
Total segment revenues* | $ | 656,812 |  |  | $ | 67,572 |  |  | $ | 60,830 |  |  | $ | 785,214 |
Cost of sales | 268,849 |  |  | 29,757 |  |  | 51,360 |  |  | 349,966 |
Gross profit | 387,963 |  |  | 37,815 |  |  | 9,470 |  |  | 435,248 |
Advertising and promotion | 98,666 |  |  | 11,827 |  |  | 1,474 |  |  | 111,967 |
Contribution margin | $ | 289,297 |  |  | $ | 25,988 |  |  | $ | 7,996 |  |  | 323,281 |
Other operating expenses |  |  |  |  |  |  |  |  |  | 84,592 |
Operating income |  |  |  |  |  |  |  |  |  | 238,689 |
Other expense |  |  |  |  |  |  |  |  |  | 79,041 |
Income before income taxes |  |  |  |  |  |  |  |  |  | 159,648 |
Benefit for income taxes |  |  |  |  |  |  |  |  |  | (219,609 | )
Net income |  |  |  |  |  |  |  |  |  | $ | 379,257 |
* Intersegment revenues of $5.6 million were eliminated from the North American OTC Healthcare segment.
| Three Months Ended December 31, 2016
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  | Household Cleaning |  | Consolidated
Total segment revenues* | $ | 177,273 |  |  | $ | 18,459 |  |  | $ | 21,031 |  |  | $ | 216,763 |
Cost of sales | 68,378 |  |  | 7,678 |  |  | 16,160 |  |  | 92,216 |
Gross profit | 108,895 |  |  | 10,781 |  |  | 4,871 |  |  | 124,547 |
Advertising and promotion | 26,800 |  |  | 3,502 |  |  | 380 |  |  | 30,682 |
Contribution margin | $ | 82,095 |  |  | $ | 7,279 |  |  | $ | 4,491 |  |  | 93,865 |
Other operating expenses** |  |  |  |  |  |  |  |  | 24,578 |
Operating income |  |  |  |  |  |  |  |  | 69,287 |
Other expense |  |  |  |  |  |  |  |  | 18,554 |
Income before income taxes |  |  |  |  |  |  |  |  | 50,733 |
Provision for income taxes |  |  |  |  |  |  |  |  | 19,092 |
Net income |  |  |  |  |  |  |  |  | $ | 31,641 |
* Intersegment revenues of $0.8 million were eliminated from the North American OTC Healthcare segment. **Other operating expenses for the three months ended December 31, 2016 includes a pre-tax net gain on divestitures of $3.4 million related primarily to e.p.t and Dermoplast. The assets and corresponding contribution margin associated with the pre-tax net gain on these divestitures are included within the North American OTC Healthcare segment.
| Nine Months Ended December 31, 2016
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  | Household Cleaning |  | Consolidated
Total segment revenues* | $ | 521,800 |  |  | $ | 53,067 |  |  | $ | 66,523 |  |  | $ | 641,390 |
Cost of sales | 198,014 |  |  | 21,722 |  |  | 51,551 |  |  | 271,287 |
Gross profit | 323,786 |  |  | 31,345 |  |  | 14,972 |  |  | 370,103 |
Advertising and promotion | 76,651 |  |  | 8,870 |  |  | 1,388 |  |  | 86,909 |
Contribution margin | $ | 247,135 |  |  | $ | 22,475 |  |  | $ | 13,584 |  |  | 283,194 |
Other operating expenses** |  |  |  |  |  |  |  |  | 130,635 |
Operating income |  |  |  |  |  |  |  |  | 152,559 |
Other expense |  |  |  |  |  |  |  |  | 60,511 |
Income before income taxes |  |  |  |  |  |  |  |  | 92,048 |
Provision for income taxes |  |  |  |  |  |  |  |  | 33,743 |
Net income |  |  |  |  |  |  |  |  | $ | 58,305 |
* Intersegment revenues of $2.2 million were eliminated from the North American OTC Healthcare segment. **Other operating expenses for the nine months ended December 31, 2016 includes a pre-tax net loss of $51.6 million related to divestitures. These divestitures include Pediacare, New Skin, Fiber Choice, e.p.t and Dermoplast and license rights in certain geographic areas pertaining to Comet. The assets and corresponding contribution margin associated with the pre-tax net loss on divestitures related to Pediacare, New Skin, Fiber Choice, e.p.t and Dermoplast are included within the North American OTC Healthcare segment, while the pre-tax gain on sale of license rights related to Comet is included in the Household Cleaning segment.
Information about our Revenues from Similar Product Groups | The tables below summarize information about our segment revenues from similar product groups.
| Three Months Ended December 31, 2017
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  | Household Cleaning |  | Consolidated
Analgesics | $ | 31,293 |  |  | $ | 160 |  |  | $ | — |  |  | $ | 31,453 |
Cough & Cold | 28,761 |  |  | 4,331 |  |  | — |  |  | 33,092 |
Women's Health | 63,107 |  |  | 2,940 |  |  | — |  |  | 66,047 |
Gastrointestinal | 29,392 |  |  | 11,251 |  |  | — |  |  | 40,643 |
Eye & Ear Care | 21,631 |  |  | 3,205 |  |  | — |  |  | 24,836 |
Dermatologicals | 22,736 |  |  | 562 |  |  | — |  |  | 23,298 |
Oral Care | 27,144 |  |  | 3,267 |  |  | — |  |  | 30,411 |
Other OTC | 1,631 |  |  | 1 |  |  | — |  |  | 1,632 |
Household Cleaning | — |  |  | — |  |  | 19,203 |  |  | 19,203 |
Total segment revenues | $ | 225,695 |  |  | $ | 25,717 |  |  | $ | 19,203 |  |  | $ | 270,615 |
| Nine Months Ended December 31, 2017
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  | Household Cleaning |  | Consolidated
Analgesics | $ | 89,931 |  |  | $ | 709 |  |  | $ | — |  |  | $ | 90,640 |
Cough & Cold | 67,738 |  |  | 13,603 |  |  | — |  |  | 81,341 |
Women's Health | 187,688 |  |  | 8,440 |  |  | — |  |  | 196,128 |
Gastrointestinal | 88,145 |  |  | 25,123 |  |  | — |  |  | 113,268 |
Eye & Ear Care | 69,437 |  |  | 8,850 |  |  | — |  |  | 78,287 |
Dermatologicals | 72,688 |  |  | 1,587 |  |  | — |  |  | 74,275 |
Oral Care | 77,026 |  |  | 9,256 |  |  | — |  |  | 86,282 |
Other OTC | 4,159 |  |  | 4 |  |  | — |  |  | 4,163 |
Household Cleaning | — |  |  | — |  |  | 60,830 |  |  | 60,830 |
Total segment revenues | $ | 656,812 |  |  | $ | 67,572 |  |  | $ | 60,830 |  |  | $ | 785,214 |
| Three Months Ended December 31, 2016
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  | Household Cleaning |  | Consolidated
Analgesics | $ | 32,439 |  |  | $ | 444 |  |  | $ | — |  |  | $ | 32,883 |
Cough & Cold | 29,803 |  |  | 4,166 |  |  | — |  |  | 33,969 |
Women's Health | 30,896 |  |  | 580 |  |  | — |  |  | 31,476 |
Gastrointestinal | 15,109 |  |  | 6,701 |  |  | — |  |  | 21,810 |
Eye & Ear Care | 23,571 |  |  | 2,997 |  |  | — |  |  | 26,568 |
Dermatologicals | 19,948 |  |  | 479 |  |  | — |  |  | 20,427 |
Oral Care | 24,129 |  |  | 3,083 |  |  | — |  |  | 27,212 |
Other OTC | 1,378 |  |  | 9 |  |  | — |  |  | 1,387 |
Household Cleaning | — |  |  | — |  |  | 21,031 |  |  | 21,031 |
Total segment revenues | $ | 177,273 |  |  | $ | 18,459 |  |  | $ | 21,031 |  |  | $ | 216,763 |
| Nine Months Ended December 31, 2016
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  | Household Cleaning |  | Consolidated
Analgesics | $ | 90,558 |  |  | $ | 1,515 |  |  | $ | — |  |  | $ | 92,073 |
Cough & Cold | 68,876 |  |  | 13,718 |  |  | — |  |  | 82,594 |
Women's Health | 97,051 |  |  | 2,151 |  |  | — |  |  | 99,202 |
Gastrointestinal | 50,495 |  |  | 17,045 |  |  | — |  |  | 67,540 |
Eye & Ear Care | 72,512 |  |  | 8,782 |  |  | — |  |  | 81,294 |
Dermatologicals | 65,598 |  |  | 1,717 |  |  | — |  |  | 67,315 |
Oral Care | 72,308 |  |  | 8,120 |  |  | — |  |  | 80,428 |
Other OTC | 4,402 |  |  | 19 |  |  | — |  |  | 4,421 |
Household Cleaning | — |  |  | — |  |  | 66,523 |  |  | 66,523 |
Total segment revenues | $ | 521,800 |  |  | $ | 53,067 |  |  | $ | 66,523 |  |  | $ | 641,390 |
Allocation of Long-Term Assets to Segments | These consolidated goodwill and intangible assets have been allocated to the reportable segments as follows:
December 31, 2017 | North American OTC Healthcare |  | International OTC Healthcare |  | Household Cleaning |  | Consolidated
(In thousands) |  |  |  |  |  |  |
Goodwill | $ | 580,934 |  |  | $ | 33,154 |  |  | $ | 6,245 |  |  | $ | 620,333 |
Intangible assets |  |  |  |  |  |  |  |
Indefinite-lived | 2,404,336 |  |  | 85,329 |  |  | 101,261 |  |  | 2,590,926 |
Finite-lived, net | 271,240 |  |  | 6,206 |  |  | 19,625 |  |  | 297,071 |
Intangible assets, net | 2,675,576 |  |  | 91,535 |  |  | 120,886 |  |  | 2,887,997 |
Total | $ | 3,256,510 |  |  | $ | 124,689 |  |  | $ | 127,131 |  |  | $ | 3,508,330 |
March 31, 2017 | North American OTC Healthcare |  | International OTC Healthcare |  | Household Cleaning |  | Consolidated
(In thousands) |  |  |  |  |  |  |
Goodwill | $ | 576,453 |  |  | $ | 32,554 |  |  | $ | 6,245 |  |  | $ | 615,252 |
Intangible assets |  |  |  |  |  |  |  |
Indefinite-lived | 2,404,336 |  |  | 83,558 |  |  | 101,261 |  |  | 2,589,155 |
Finite-lived, net | 287,056 |  |  | 6,468 |  |  | 20,934 |  |  | 314,458 |
Intangible assets, net | 2,691,392 |  |  | 90,026 |  |  | 122,195 |  |  | 2,903,613 |
Total | $ | 3,267,845 |  |  | $ | 122,580 |  |  | $ | 128,440 |  |  | $ | 3,518,865 |

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599 + Details
Name: | us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8813-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8736-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration